-
Ozempic And Other GLP-1RA Use Associated With NAION Eye Side Effect
New 2026 Medical Article Published By JAMA Network Open Investigates Drug Safety Issue (Posted by Tom Lamb at Drug Injury Watch) An increasingly known but still-developing drug safety issue is that of Ozempic and other GLP-1RA use…
-
Tavneos Warnings For VBDS Liver Side Effect Increased In April 2026
Tavneos Drug Label Change By Amgen Just 2 Days After Tavneos Drug Recall Statement By FDA (Posted by Tom Lamb at Drug Injury Watch) The Tavneos drug safety issue has an interesting new development. On April 29,…
-
Tavneos Liver Injury Drug Safety Communication Issued by FDA in Late March 2026
Just 2 Months Earlier, Amgen Refused an FDA Request to Withdraw Tavneos; Will There Be a Tavneos Recall Soon? (Posted by Tom Lamb at Drug Injury Watch) On March 31, 2026, the FDA issued a Tavneos liver…
-
Wegovy and Ozempic Vision Loss: Wegovy Rate 5x Higher vs. Ozempic, Men 3x More Often vs. Women
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Semaglutide Study 2026 Data Analysis (Posted by Tom Lamb at Drug Injury Watch) A March 2026 British Journal of Ophthalmology medical journal article, “Ischemic optic neuropathy with semaglutide: global observational analysis…
-
While Rybelsus Pills Are Being Replaced With Pills Called Ozempic, Semaglutide NAION Risk Remains
But the January 2026 Rybelsus-Ozempic Drug Label Still Has No Warnings for NAION Vision Loss Side Effect (Posted by Tom Lamb at Drug Injury Watch) The “Revised: 1/2026” Prescribing Information document for “RYBELSUS and OZEMPIC tablets” caused…
